Cancer statistics, 2013, CA: A Cancer Journal for Clinicians, vol.287, issue.suppl 5, pp.11-30, 2013. ,
DOI : 10.3322/caac.21166
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO- OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 15 mars, ):1234?44. 4. Eisenkop SM, Spirtos NM, Friedman RL, Lin W-CM, 2009. ,
Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial, JNCI Journal of the National Cancer Institute, vol.97, issue.8, pp.560-566, 2005. ,
DOI : 10.1093/jnci/dji102
Potential Role of Lymphadenectomy in Advanced Ovarian Cancer: A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials, Journal of Clinical Oncology, vol.28, issue.10, pp.1733-1742, 2010. ,
DOI : 10.1200/JCO.2009.25.3617
The role of lymph node resection in ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database, BJOG: An International Journal of Obstetrics & Gynaecology, vol.202, issue.12, pp.1451-1459, 2010. ,
DOI : 10.1111/j.1471-0528.2010.02633.x
lymphorrhea, and lymphedema after laparoscopic and open endometrial cancer staging, Ann Surg Oncol. janv, vol.19, issue.1, pp.259-67, 2012. ,
An Analysis of the Risk Factors and Management of Lymphocele after Pelvic Lymphadenectomy in Patients with Gynecologic Malignancies, Cancer Research and Treatment, vol.36, issue.6, pp.377-83, 2004. ,
DOI : 10.4143/crt.2004.36.6.377
Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis A randomized study comparing the use of the Ligaclip with bipolar energy to prevent lymphocele during laparoscopic pelvic lymphadenectomy for gynecologic cancer, Obstet Gynecol. janv Am J, vol.61, issue.14, 1983. ,
Prevention of lymphoceles and gynaecologic cancers]. Gynécologie Obstétrique Fertil, déc, vol.39, issue.12, pp.698-703, 2011. ,
A phase 3 trial of bevacizumab in ovarian cancer, N Engl J Med. 29 déc, vol.365, issue.26, pp.2484-96, 2011. ,
Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? The Oncologist Emerging treatment options for management of malignant ascites in patients with ovarian cancer, 1242?51. 22. Eskander RN, pp.395-404, 2009. ,
Malignant ascites in ovarian cancer and the role of targeted therapeutics, Anticancer Res. avr, vol.34, issue.4, pp.1553-61, 2014. ,
Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls, Lancet. 26 janv, vol.371, issue.9609, pp.303-317, 2008. ,
Survie des personnes atteintes de cancer en France, 1989-2007-Etude à partir des registres du réseau Francim. Saint Maurice: Institut de Veille Sanitaire ,
Penetrance, Journal of Clinical Oncology, vol.25, issue.11 ,
DOI : 10.1200/JCO.2006.09.1066
Familial breastovarian cancer syndromes: BRCA1 and BRCA2, 1329?33. 29. Berchuck A, pp.157-66, 1998. ,
Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers, Clinical Cancer Research, vol.10, issue.7, pp.2473-81, 2004. ,
DOI : 10.1158/1078-0432.CCR-1029-3
BRCA1 and BRCA2 as ovarian cancer susceptibility genes, 1651?6. 33. Chetrit A, 2005. ,
DOI : 10.1093/carcin/bgi136
Institut National du Cancer, 2009. ,
Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants, Journal of Medical Genetics, vol.103, issue.2, pp.108-121, 2014. ,
DOI : 10.1136/jmedgenet-2013-102015
The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease, American Journal of Obstetrics and Gynecology, vol.170, issue.4, pp.1099-105, 1994. ,
DOI : 10.1016/S0002-9378(94)70104-0
Epidémiologie des tumeurs de l'ovaire. EMC gynécologie, p.40, 2012. ,
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features, Virchows Archiv, vol.100, issue.3, pp.237-286, 2012. ,
DOI : 10.1007/s00428-012-1203-5
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer, The Journal of Pathology, vol.59, issue.4, pp.451-457, 2001. ,
DOI : 10.1002/path.1000
Tubal ligation and risk of ovarian cancer, The Lancet, vol.358, issue.9284, pp.844-887, 2001. ,
DOI : 10.1016/S0140-6736(01)05992-X
A candidate precursor to serous carcinoma that originates in the distal fallopian tube, The Journal of Pathology, vol.73, issue.1, pp.26-35, 2007. ,
DOI : 10.1002/path.2091
The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome, 230?6. 45. Kindelberger DW, 2006. ,
DOI : 10.1097/01.pas.0000180854.28831.77
Serous carcinogenesis in the fallopian tube: a descriptive classification Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors, Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. janv Cancer Res. 15 mai, vol.2758, issue.110, pp.2095-2102, 1998. ,
Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary, Cancer Res. 15 déc, vol.60, issue.24, pp.7052-7058, 2000. ,
Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the ??-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis, 605?19. 50. Singer G, 2005. ,
DOI : 10.1016/j.humpath.2005.03.005
low-grade ovarian serous carcinoma Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation, Mutations in BRAF and KRAS characterize the development of):484?6. 51. Singer G, pp.218-242, 2003. ,
Surface epithelial-stromal tumours (Ch 2: tumours of the ovary and peritoneum), pp.117-162, 2003. ,
Classification histopathologique des tumeurs ovariennes ,
Grading ovarian serous carcinoma using a two-tier system, Am J Surg Pathol. avr, vol.28, issue.4, pp.496-504, 2004. ,
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory, The American Journal of Surgical Pathology, vol.34, issue.3, pp.433-476, 2010. ,
DOI : 10.1097/PAS.0b013e3181cf3d79
New insights into ovarian cancer pathology, Annals of Oncology, vol.23, issue.suppl 10 ,
DOI : 10.1093/annonc/mds300
URL : http://annonc.oxfordjournals.org/cgi/content/short/23/suppl_10/x111
Chirurgie des tumeurs ??pith??liales malignes de l'ovaire, EMC - Techniques chirurgicales - Gyn??cologie, vol.4, issue.1, p.58, 2009. ,
DOI : 10.1016/S1624-5857(09)73033-9
Cancer de l'ovaire: Diagnostic, bilan, stratégie thérapeutique ,
Staging classification for cancer of the ovary, fallopian tube, and peritoneum):1?5. 61. FIGO Cancer Committee Staging Announcement. FIGO staging of ovarian cancer Ovarian Cancer Overview, Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. janv Gynecologic Oncology, vol.124, issue.1, p.62, 1986. ,
cancer.org/cancer/ovariancancer/overviewguide/ ovarian-cancer- overview-survival. 63 ,
International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer, Prognostic and predictive factors in epithelial ovarian cancer]. Bull Cancer425?37. 65. Bonneau, C. Étude des marqueurs prédictifs de chimiorésistance dans le cancer, 2009. ,
Mémoire de Master 2 de sciences chirurgicales; Directeurs de mémoire, pp.2012-66 ,
Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer, Am J Obstet Gynecol. févr, vol.202, issue.2, 2010. ,
Cancer de l'ovaire TRAITEMENT CHIRURGICAL. Institut National du Cancer, agence sanitaire et scientifique chargée de coordonner la politique de lutte contre le cancer en France, 1969. ,
Aggressive surgical effort and improved survival in advanced-stage ovarian cancer Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review, Obstet Gynecol. janv, vol.107, issue.1, 2006. ,
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis, 257?64. 72. Bristow RE, pp.1070-1076, 2006. ,
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in patients with gynaecological malignancies, N Engl J Med. 2 sept Cochrane Database Syst Rev, vol.3636, issue.75, pp.7387-76, 2010. ,
Recommandations 2008 pour la prise en charge des patientes atteintes de tumeurs épithéliales malignes de l'ovaire « Traitement médical de première ligne ». FNCLCC, 2008. ,
open-label, randomised controlled trial Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial, 1331?8. 78. Pignata S,):396?405. 79. Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries, pp.169-82, 2005. ,
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer, Br J Cancer. 24 mars, vol.100, issue.6, pp.971-979, 2009. ,
The prognostic significance of angiogenesis in epithelial ovarian carcinoma, Clin Cancer Res Off J Am Assoc Cancer Res. mars, vol.5, issue.3, pp.587-91, 1999. ,
Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science. 26 mai, pp.1171-1176, 2006. ,
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer, Eur J Cancer Oxf Engl déc, vol.49, issue.87, pp.3831-3839, 1990. ,
A RADICAL OPERATION FOR FIXED OVARIAN TUMOURS, BJOG: An International Journal of Obstetrics and Gynaecology, vol.207, issue.11 ,
DOI : 10.1111/j.1471-0528.1968.tb02901.x
Pelvic and paraaortic lymphocysts after radical surgery because of cervical and ovarian cancer, American Journal of Obstetrics and Gynecology, vol.161, issue.4, pp.937-978, 1989. ,
DOI : 10.1016/0002-9378(89)90757-6
Ovarian cancer in the elderly: Impact of surgery on morbidity and survival, European Journal of Surgical Oncology (EJSO), vol.37, issue.6, pp.537-579, 2011. ,
DOI : 10.1016/j.ejso.2011.03.136
Prevention of lymphoceles using Floseal(®) and Coseal(®) after laparoscopic lymphadenectomy in patients with gynecologic malignancies, J Minim Invasive Gynecol, vol.93, 2014. ,